Stock Research for ENTA

ENTA

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ENTA Stock Chart & Research Data

The ENTA chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ENTA chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ENTA Due diligence Resources & Stock Charts

The ENTA stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ENTA Detailed Price Forecast - CNN Money CNN View ENTA Detailed Summary - Google Finance
Yahoo View ENTA Detailed Summary - Yahoo! Finance Zacks View ENTA Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ENTA Trends & Analysis - Trade-Ideas Barrons View ENTA Major Holders - Barrons
NASDAQ View ENTA Call Transcripts - NASDAQ Seeking View ENTA Breaking News & Analysis - Seeking Alpha
Spotlight View ENTA Annual Report - CompanySpotlight.com OTC Report View ENTA OTC Short Report - OTCShortReport.com
TradeKing View ENTA Fundamentals - TradeKing Charts View ENTA SEC Filings - Bar Chart
WSJ View Historical Prices for ENTA - The WSJ Morningstar View Performance/Total Return for ENTA - Morningstar
MarketWatch View the Analyst Estimates for ENTA - MarketWatch CNBC View the Earnings History for ENTA - CNBC
StockMarketWatch View the ENTA Earnings - StockMarketWatch MacroAxis View ENTA Buy or Sell Recommendations - MacroAxis
Bullish View the ENTA Bullish Patterns - American Bulls Short Pains View ENTA Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ENTA Stock Mentions - StockTwits PennyStocks View ENTA Stock Mentions - PennyStockTweets
Twitter View ENTA Stock Mentions - Twitter Invest Hub View ENTA Investment Forum News - Investor Hub
Yahoo View ENTA Stock Mentions - Yahoo! Message Board Seeking Alpha View ENTA Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for ENTA - SECform4.com Insider Cow View Insider Transactions for ENTA - Insider Cow
CNBC View ENTA Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ENTA - OTC Markets
Yahoo View Insider Transactions for ENTA - Yahoo! Finance NASDAQ View Institutional Holdings for ENTA - NASDAQ


Stock Charts

FinViz View ENTA Stock Insight & Charts - FinViz.com StockCharts View ENTA Investment Charts - StockCharts.com
BarChart View ENTA Stock Overview & Charts - BarChart Trading View View ENTA User Generated Charts - Trading View


Latest Financial News for ENTA

Analysing NVR, DPZ, ENTA And QLYS Stocks
Posted on Monday May 21, 2018

NVR’s (NVR) net income has grown at a 3-year and 5-year average of 24% and 24.3% respectively. The company’s pre-tax margin grew from 9.9% in 2013 to 13.4% in 2017. The stock prices have beaten the residential construction industry between 2013 and 2017. The stock was beaten in 2013 and 2016 by the S&P 500. The market cap had gained 188% between 2013 and 2017.


Total Returns and Sector Exposure for Growth Indexes—Continued
Posted on Monday May 21, 2018

The S&P 900 Growth and S&P 900 Pure Growth indexes have three-year annualized returns of 13% and 9.7%, respectively. They have five-year annualized returns of 15% and 12.7%, respectively. They have YTD (year-to-date) returns of 5.4% and 6.1%, respectively.


AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
Posted on Monday May 21, 2018

AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.


Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study
Posted on Friday May 18, 2018

Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.


Enter a stock symbol to view the stock details.